phase ii cf data discontinu cystinosi
eloxx end cash million follow workforc reduct eloxx guid
cash fund oper eloxx focus develop
cystic fibrosi report phase ii data mutant patient eloxx
discontinu phase ii studi fo cystinosi lower white blood cell
cystin level seen reduct clinic benefici level achiev eloxx
believ mechan may better serv kidney diseas caus
nonsens mutat prepar ind autosom domin polycyst kidney
diseas adpkd eloxx also advanc pipelin retin candid present
preclin data arvo may reiter overweight rate howev
lower price target remov valu cytinosi
top-lin phase ii cystic fibrosi data phase ii studi
enrol patient europ mutat
preval nonsens mutat affect cf patient patient
receiv daili subcu inject establish go-forward dose
base chang sweat chlorid safeti primari endpoint
measur eloxx track report top-lin phase ii data eloxx give
oral present entitl beyond modul approach involv gene edit
altern channel european cystic fibrosi confer earli june
discontinu cystinosi phase ii adpkd plan clinic benefit
observ phase ii cystinosi studi therefor eloxx discontinu
cohort degre reduct cystin level clean safeti
eloxx believ de-risk applic kidney diseas eloxx target
adpkd preclinc studi shown dose-depend read-through across
common allel preclin studi on-going advanc
program toward ind
build preclin data retin diseas eloxx continu advanc intravitr
read-through compound retin diseas compani state singl intravitr
inject read-through compound restor function gene involv
melanin product found retina eloxx state rential program
focu usher syndrom type repres case restor mutat
gene eloxx present new preclin data read-through compound
retin diseas arvo form may
may fail clinic fail gain regulatori approv eloxx may unabl file
ind compani like requir futur fund
eloxx develop drug treat genet diseas caus nonsens mutat
debt total capit
piper sandler seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
reiter overweight rate howev trim price target
remov valu cystinosi reduc burn rate compani focus
cystic fibrosi reduc headcount price target base project
enterpris valu million million
continu valu cf million appli standard
multipl sale million discount back continu
valu cf europ million appli multipl sale
million discount back view discount rate cf
high adjust phase ii data expect
remov valu cystinosi compani discontinu phase ii
studi prior valu cystinosi million appli multipl
sale million europ million appli multipl
sale million discount back
continu add million eloxx preclin usher syndrom program
eloxx end cash million owe debt million svb
westriv eloxx institut workforc reduct order extend cash run way toward
thu add project net cash million vs previous subtract
net debt million divid project market cap million
million share arriv lower price target pleas see exhibit
page
thousand except per share
research develop
gener administr
incom expens
net loss attribut common stockhold
compani report piper sandler estim
current disclosur inform compani found
